Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Paltusotine→

Paltusotine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2172870-89-0
Molecular formula
C27H22F2N4O
Molecular weight
456.5 g/mol
Drug class
Oral non-peptide somatostatin receptor 2 (SSTR2) agonistacromegaly therapy
Mechanism of action
Activates somatostatin receptor 2 on pituitary somatotroph cells, reducing growth hormone secretion and downstream circulating insulin-like growth factor-1 (IGF-1).
Indications / reported uses
  • Treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option under the US PALSONIFY indication (approved 25 September 2025)

Sources: US FDA — PALSONIFY approval and indication · FDA Orphan Drug database — Paltusotine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Paltusotine Environmental Risk Assessment (ERA) (the Paltusotine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.